Available online on 15 Jun, 2026 at https://ijdra.com/index.php/journal
International Journal of Drug Regulatory Affairs
Published by Diva Enterprises Pvt. Ltd., New Delhi
Associated with Delhi Pharmaceutical Sciences & Research University

Review Article Open Access

Driving First-Cycle ANDA Approvals Through Strategic Regulatory Planning

Piyush Modi [a,*], Jigneshkumar Modasiya [b], Dhaval Desai [c]

[a]*Director, Regulatory Affairs, Amneal Pharmaceuticals of NY LLC, New York, USA.*
[b]*Director, Regulatory Affairs, Amneal Pharmaceuticals, Piscataway, NJ, USA.*
[c]*Director, Regulatory Affairs, Zydus Pharmaceuticals USA Inc, Pennington, NJ, USA.*

Abstract

Getting first-cycle approval for Abbreviated New Drug Applications (ANDAs) is crucial for generic drug sponsors, especially when quick market entry and regulatory risks are at stake. Even though the U.S. Food and Drug Administration has established clear review processes and goals under the Generic Drug User Fee Amendments (GDUFA), many ANDAs remain delayed by avoidable problems in bioequivalence, chemistry, manufacturing, and controls, labeling, and facility compliance.

This article looks at what affects first-cycle ANDA approval. It highlights the importance of making early regulatory decisions, spotting risks before filing, and keeping the team on the same page. It also covers how to prepare before and after submission, maintain quality, answer review questions, and get ready for inspections.

The article uses performance metrics and real-world examples to show how sponsors can shorten review times and improve their chances of approval. Careful planning and steady execution help organizations avoid last-minute changes and achieve more predictable, timely approvals.

Conclusion: A well-defined and proactive regulatory strategy enhances the prospects of first-cycle ANDA approval. Early identification and mitigation of potential risks, high-quality submission preparation, and effective cross-functional collaboration help minimize review cycles and facilitate more efficient, predictable, and timely regulatory approvals.

Keywords: ANDA; First-cycle approval; GDUFA; Regulatory planning; Submission quality; Generic drugs; CMC; FDA

Article Info: Received 21 May 2026; Review Completed 13 Jun 2026; Accepted 15 Jun 2026

Cite this article as:
Modi P, Modasiya J,Desai D.Driving First-Cycle ANDA Approvals Through Strategic Regulatory Planning. Int. J. Drug Reg. Affairs [Internet]. 2026 Jun 15 [cited 2026 Jun 15]; 14(2):84-89. Available from: http://ijdra.com/index.php/journal/article/view/921

DOI: https://doi.org/10.22270/ijdra.v14i2.921
*Corresponding author. E-mail address: piyushhmodi@yahoo.in (P. Modi)

1. Introduction

The generic pharmaceutical industry makes affordable medicines available to more patients, and Abbreviated New Drug Applications (ANDAs) are primarily used to demonstrate that generics are therapeutically equivalent to reference-listed drugs (RLDs). In the U.S., the Food and Drug Administration (FDA) reviews ANDAs based on bioequivalence (BE), chemistry, manufacturing, and controls (CMC), labeling, and inspection readiness. Generic Drug User Fee Amendments (GDUFA) has made reviews clearer and faster, but obtaining first-cycle approval remains difficult. (1–5)

First-cycle ANDA approval matters for both regulatory and business reasons. It influences how quickly a product reaches the market, development costs, and a company's reputation. FDA data show that first-cycle approvals have remained below approximately 20 percent of total approvals in recent years. (1,3,6) Many delays are due to issues that could have been addressed earlier, such as missing CMC documentation, insufficient weak-bioequivalence support, DMF alignment problems, differences from the reference product, and failure to meet manufacturing-readiness requirements. (7,8)

Generic Drug User Fee Amendments III (GDUFA III) encourages sponsors to submit high-quality applications early and keep in touch with the FDA to reduce review cycles. (9) At the same time, products are becoming more complex, increasing regulatory risks. Complex generics often need more than one review cycle if the submission is not fully prepared. (10) In this article, first-cycle approval means that an ANDA is approved during the initial FDA review, without requiring additional review cycles. **Figure 1** shows the main activities from product selection to submission and inspection readiness.

2. ANDA Review Structure and Common FDA Deficiency

As explained in the Introduction, the FDA reviews ANDAs through a structured, multidisciplinary process led by the Office of Generic Drugs (OGD). The Office of

Pharmaceutical Quality (OPQ) handles CMC assessments, while the Office of Bioequivalence (OB) reviews BE using in vivo or in vitro methods. At the same time, FDA teams check proposed labeling for consistency with the RLD, review Drug Master Files (DMFs), and assess facility compliance, including readiness for pre-approval inspection when needed. (11,12) This integrated review model is designed to ensure pharmaceutical equivalence, bioequivalence, and consistent product quality at approval.



Figure 1. Integrated Framework for First Cycle ANDA Approval

Even with this review process, FDA assessments show that about 30-36% of major Complete Response Letters (CRLs) in the first cycle are due to CMC issues. These often include unclear control strategies, incomplete descriptions of impurities, missing stability data, or a lack of manufacturing readiness. (7,8) Bioequivalence problems account for about 15-20% of major deficiencies, such as poor study design, insufficient support for highly variable drugs, or weak statistical analysis and reporting. (8) **Table 1** lists common deficiencies found during ANDA review, their usual causes, and ways to avoid them.

Table 1. Common ANDA Deficiencies and Preventive Actions

Common deficiency	Reason for deficiency	Regulatory strategy
CMC	Weak control strategy, impurity control, stability trend	QbD, early OPQ alignment, PDEV meeting (7,8)
BE	Study design misfit	Pilot studies, PDEV meeting (8)
Labeling	Misalignment with the RLD	Regular checking for RLD labeling update (7,9)
DMF	Hidden facility, impurity control	Pre-submission DMF review, discussion with DMF holder (11,12)
Inspection	Data integrity gaps	Early PAI readiness (11,12)

BE, bioequivalence**; CMC,** chemistry, manufacturing, and controls**; CQA,** critical quality attribute**; DMF,** drug master file**; OPQ,** Office of Pharmaceutical Quality**; PAI,** pre-approval inspection**; PDEV,** product development meeting**; QbD**, quality-by-design; **RLD,** reference listed drug.

Labeling issues, for example, differences from the reference-listed drug (RLD), missing patent or exclusivity details, unresolved carve-outs, and facility problems identified during pre-approval inspections, often lead to approval delays and additional review cycles. (7,9) FDA data show that manufacturing and drug product issues are the most common major problems in the first cycle, regardless of sponsor or product type. (8) This highlights the need for complete CMC packages and inspection-ready facilities at the time of filing, aligning with GDUFA III's focus on improved submission quality,

early FDA communication, and strong cross-departmental teamwork. (9,13)

3. Regulatory planning before ANDA submission

Regulatory strategy usually begins by identifying key risks early and addressing them in a structured manner. Teams use risk assessments, experience, and Quality by Design principles to review bioequivalence plans, formulation, testing methods, manufacturing controls, labeling, and inspection readiness. (7,14)

A clear CMC approach is also important and is usually set up early. This means defining critical quality attributes, setting the control strategy, and ensuring that development, exhibit batches, and commercial manufacturing are aligned. (7,15)

Planning for bioequivalence is another common challenge in the first cycle. Choosing the right study type (fasted or fed), using replicate or adaptive designs, and setting clear statistical methods for highly variable drugs can lower regulatory risk. (8,16) When possible, using in vitro–in vivo correlation or biowaiver methods, backed by robust dissolution testing, can strengthen the bioequivalence case and reduce the need for additional clinical studies. (16)

Using FDA regulatory tools early is important for getting approval in the first review cycle. Sponsors should use product-specific guidance, controlled correspondence, and pre-ANDA meetings, especially for complex products, to understand what the FDA expects before submitting. (9,11) Meeting refuse-to-receive standards ensures submissions are complete and reduces the risk of early rejection. (17) Preparing facilities early with mock inspections, process checks, and data audits also helps avoid inspection-related problems. (18) All these steps support a proactive, risk-based approach to increase first-cycle approvals. (6,9)

4. Regulatory planning at the time of ANDA submission

A clear, well-prepared dossier helps speed up approval. First-cycle approvals are more likely when CMC, BE, labeling, and facility details are consistent. Providing clear information on quality attributes, dissolution data, batches, and manufacturing processes makes the review process smoother and leads to fewer follow-up questions. (11,7) Ensuring DMFs are properly referenced and authorized is a common challenge, especially for products with multiple drug substances, non-standard excipients, and new packaging. Problems such as outdated authorization letters, mismatches in DMF content, or discrepancies between ANDA descriptions and DMFs often cause CMC issues or lead to rejection. (19,20) Clear links between DMF commitments, ANDA content, and manufacturing processes are important for submission readiness. Sponsors who check DMF quality and consistency before filing usually get fewer CMC questions and faster ANDA acceptance. (7,15)

To avoid major problems, companies need robust internal review processes that align with FDA assessments. Running internal mock FDA reviews using current guidance, recent Complete Response Letters, and trends in Office of Pharmaceutical Quality Deficiency helps spot and fix issues before submission. (7) Careful dossier preparation, internal quality checks, and inspection-ready documents support a 'right-first time' approach. (6,9) A well-prepared ANDA makes the application clearer for FDA reviewers and increases the chances of first-cycle approval, which also benefits the business.

4.1Inspection Readiness and Compliance Strategy

Pre-approval inspections (PAIs) are a key part of the ANDA approval process and can sometimes delay or prevent approval, even for strong applications. The FDA uses PAIs to ensure that manufacturing sites, including contract manufacturers and API suppliers, can reliably produce the generic drug product in accordance with current good manufacturing practices. (11)

When several manufacturing sites are involved, the risk of inspection errors increases because different production and testing steps occur at different locations. A problem at one site can affect the whole application, even if internal quality systems are in place. (11,19) Failing to closely monitor the quality systems of contract manufacturers can lead to inspection findings that delay approval, especially for new or recently changed facilities. (7,15) Inspection results also depend on team training and consistent documentation across functions. (7) Differences between documented procedures and actual practices often lead to observations. (18,21) Addressing inspection readiness early in development helps lower these risks. (9) **Figure 2** shows inspection readiness as a staged approach supported by data integrity, Standard Operating Procedure (SOP) alignment, and personnel readiness.



Figure 2. Pre-Approval Inspection Readiness Model

SOP: Standard Operating Procedure

5. Regulatory planning after ANDA submission

Post-submission activities can affect whether an ANDA is approved in the first review cycle. After the application is accepted, teams need to stay coordinated and answer FDA questions quickly and consistently. If this is not managed well, small issues can add up and lead to a Complete Response Letter. Information Requests are a normal part of ANDA review and usually focus on specific scientific or regulatory topics. (11,22) When responses are timely and backed by existing data, many issues can be resolved without delaying the review cycle. (7,23)Handling these requests needs clear ownership and strong team coordination. Responses based on existing data are usually resolved more easily during review. (7) Adding new or unclear information late in the process often leads to more questions. (11,22)

Labeling discussions can also affect how smoothly an ANDA moves toward approval. Usually, generic labeling must match the reference listed drug, with only small differences allowed for manufacturer details or approved carve-outs for patents or exclusivities. (24,25) Finding Section VIII carve-outs early helps avoid delays later, especially when protected uses or safety language are involved. Problems often arise when carve-outs are not clearly explained or when the proposed labeling could be misinterpreted as safe for use. (24,26)Addressing labeling comments usually needs coordination between regulatory and legal teams. When planning is done early and matches patent and exclusivity positions, responses are usually more straightforward. (7) Overall, Information Requests and labeling discussions affect review timelines and are closely linked to submission quality. (11)

6. Case Examples

The following anonymized case studies show common risks in ANDA programs and how teams handled them during FDA review.

Case 1. Early Bioequivalence Strategy

In one case involving an immediate-release oral solid dosage form, the sponsor identified a potential risk of high intrasubject variability in early pharmacokinetic studies. Instead of going straight to a standard two-way crossover bioequivalence study, the team ran a pilot study to understand the variability better. Based on those results, they chose a reference-scaled replicate design that meets FDA expectations for highly variable drugs.

In the ANDA, the team explained the statistical approach and acceptance criteria in practical terms, citing prior FDA decisions and guidance. When the Office of Bioequivalence asked follow-up questions about variability and the scaling method, the team answered using the data and reasoning they had already prepared. The issue was resolved during the review without the need for a Complete Response Letter.

In this case, the team addressed variability early and revised the study design before submission. This approach helped avoid additional clinical work and allowed the review to move forward without delay.

Case 2. Facility Readiness

A second example involves a drug product made by a contract manufacturing organization. Based on past experience, the sponsor expected facility-related issues could affect approval, so they began working on PAI readiness early rather than waiting until after submission. This included conducting mock FDA inspections, improving data controls, and ensuring site procedures matched those described in the ANDA.

During the FDA's pre-approval inspection, reviewers examined how the site transitioned from development to commercial production. The inspection found no compliance issues that affected the review, so the application moved forward.

7.Metrics and KPIs for First-Cycle Approval Success

Clear, regulator-focused metrics and key performance indicators (KPIs) are important for improving first-cycle ANDA approval rates. While the first-cycle approval rate is a key outcome, other metrics help identify gaps and support ongoing improvement during development, submission, and post-submission. (9,27)

The first-cycle approval rate, or the percentage of ANDAs approved without a Complete Response Letter, is one of the best indicators of ANDA submission quality. Examining the root causes of CRLs helps explain why some applications require more than one review cycle. Breaking down CRL comments into specific areas, like CMC control strategy or data integrity, shows where improvements are needed. Organizations that track these trends typically experience fewer recurring issues and achieve better review efficiency over time. (7,8)

Inspection results can be used as KPIs for compliance. These include inspection pass rates, Form 483 observations, and inspection-related CRLs. (8,28) Tracking these across sites helps spot issues earlier and improve oversight. (9,21) Together, these metrics provide a practical, evidence-based approach to measuring and improving first-cycle ANDA approval performance. (9)

8. Future Outlook

ANDA approvals will be shaped by ongoing regulatory updates, more complex products, and higher expectations for proactive, science- and risk-based work. Early scientific planning, strong control strategies, and new bioequivalence methods will be important. FDA programs that support model-informed drug development, real-world evidence, and better scientific communication point to a more predictable regulatory process that sponsors should use. (27,29)

Digital transformation, the use of Artificial Intelligence (AI) tools, and strong data governance are becoming increasingly important in ANDA development. Organizations that invest in these areas can better manage risks and respond to regulatory questions. (7,9) Regulatory convergence and comparability protocols also help by making it easier to manage changes over time. (30,31)

Organizations that see regulatory excellence as an ongoing process, from product selection to post-submission activities, are usually better positioned for success. As GDUFA continues to push for shorter review cycles and faster patient access, first-cycle approval is becoming less of a target and more of a practical requirement, with clear effects on portfolio value and competition in the generic pharmaceutical market. (9,12)

Future growth in the generic pharmaceutical sector is expected to be driven by increasing opportunities in complex generics, drug-device combination products, and products with challenging bioequivalence requirements. Advances in analytical technologies, predictive modeling, and advanced manufacturing platforms are enabling more efficient product development and may help reduce development risks and timelines. Furthermore, greater global regulatory harmonization and increased use of innovative scientific approaches are expected to facilitate more streamlined development and approval pathways. Companies that strategically invest in these capabilities and adapt to the evolving regulatory environment will be better positioned to maintain competitiveness and expand patient access to high-quality, affordable generic medicines.(32)

9. Conclusion

First-cycle ANDA approval usually comes from good planning, execution, and timely communication with the Agency, not luck. At every stage, from development to post-submission, focusing on avoidable issues can prevent extra review cycles, market delays, and higher costs. Sponsors who invest early in science-based regulatory planning, use AI-supported review tools, and make sure they are ready for submission and inspection tend to achieve more consistent and efficient approvals. When regulatory strategy is managed throughout the process, first-cycle approval becomes more likely. Keeping up quality, managing risk, and executing well also lead to more predictable timelines and faster patient access.

Acknowledgments

The authors thank professional colleagues for their insights into regulatory strategy and ANDA development.

Conflict of Interest

The author declares that there is no conflict of interest regarding the publication of this article.

Financial Disclosure statement:

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Disclaimer

The views and opinions expressed in this article are solely those of the author and do not reflect the official policies, positions, or endorsements of any institution, organization, or employer associated with the author.

Reference

1. U.S. Food and Drug Administration. Generic Drugs Program Activities Report FY 2023 [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2023-monthly-performance
2. U.S. Food and Drug Administration. ANDA Program Statistics Overview [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from: https://www.fda.gov/media/183116/download
3. U.S. Food and Drug Administration. Generic Drugs Program Activities Report FY 2024 [Internet]. Silver Spring (MD): FDA; 2026 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2024-monthly-performance
4. Chazin H, Woo J, Han J, et al. FDA's generic drug program: decreasing time to approval and number of review cycles. Ther Innov Regul Sci [Internet]. 2020 [cited 2026 May 21];54:758–763. Available from: doi: 10.1007/s43441-019-00016-2
5. Indian Pharmaceutical Alliance. Focus on First Cycle Approval of ANDAs: Regulatory Best Practices [Internet]. 2021 [cited 2026 May 21]. Available from: https://www.ipa-india.org/sites/default/files/2025-07/Regulatory-Best-Practices-First-Cycle-ANDA-Approvals.pdf
6. U.S. Food and Drug Administration. Generic Drugs Program Activities Report FY 2025 [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2025-monthly-performance
7. Pawar J, Hegde N, Sharma S. Focusing on first-cycle approval in ANDA submission: understanding common deficiencies and case study insights. Ther Innov Regul Sci [Internet]. 2025 [cited 2026 May 21];59:426–437. Available from: doi: 10.1007/s43441-025-00755-5
8. Kozak D. Analysis of ANDA major bioequivalence deficiencies and approval cycle trends [Internet]. Paper presented at: GRx+Biosims; 2024 Oct 21 [cited 2026 May 21]. Available from: https://accessiblemeds.org/wp-content/uploads/2024/12/GRxBiosims-2024-PPT-Darby-Kozak.pdf
9. U.S. Food and Drug Administration. GDUFA Performance Reports (GDUFA I–III) [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from: https://www.fda.gov/about-fda/user-fee-performance-reports/gdufa-performance-reports
10. Jiao K, Gupta R, Fox E, et al. Characteristics of recent generic drug approvals by the US Food and Drug Administration. JAMA Netw Open [Internet]. 2019 [cited 2026 May 21];2(10):e1913029. Available from: doi:10.1001/jamanetworkopen.2019.13029
11. U.S. Food and Drug Administration. ANDA Review Process [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/generic-drugs/anda-review-process
12. U.S. Food and Drug Administration. Office of Generic Drugs Annual Report [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:

https://www.fda.gov/drugs/generic-drugs/annual-reports
13. U.S. Government Accountability Office. Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle [Internet]. GAO-19-565; 2019 [cited 2026 May 21]. Available from: https://www.gao.gov/products/gao-19-565
14. Lionberger RA, Lee SL, et al. Quality by design concepts for ANDAs. AAPS J [Internet]. 2008 [cited 2026 May 21];10(2):268–276. Available from: doi:10.1208/s12248-008-9026-7
15. Kulkarni SB, Gaikwad VL. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the FDA. J Pharmacol Toxicol Methods [Internet]. 2023 [cited 2026 May 21];123:107295. Available from: doi:10.1016/j.vascn.2023.107295
16. U.S. Food and Drug Administration. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/media/87219/download
17. U.S. Food and Drug Administration. ANDA Submissions: Refuse to Receive Standards [Internet]. Silver Spring (MD): FDA; 2022 [cited 2026 May 21]. Available from: https://www.fda.gov/media/86660/download
18. U.S. Food and Drug Administration. Form 483 Inspection Observations Data [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 May 21]. Available from: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
19. U.S. Food and Drug Administration. Drug Master Files [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs
20. U.S. Food and Drug Administration. Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa
21. Gupta A, Sharma AK. A study of submissions of abbreviated new drug applications [Internet]. 2024 [cited 2026 May 21]. Available from: https://www.ijarst.in/public/uploads/paper/650701714115121.pdf
22. U.S. Food and Drug Administration. Issuance of Information Requests and Discipline Review Letters for ANDAs [Internet]. MAPP 5220.5. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from: https://www.fda.gov/media/109649/download
23. U.S. Food and Drug Administration. Good ANDA Submission Practices [Internet]. Silver Spring (MD): FDA; 2022 [cited 2026 May 21]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-anda-submission-practices-guidance-industry
24. U.S. Food and Drug Administration. Labeling for Human Prescription Drug and Biological Products [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/laws-acts-and-rules/fdas-labeling-resources-human-prescription-drugs
25. U.S. Food and Drug Administration. Hatch-Waxman Letters [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters
26. Chan C. Best practices for generic drug labeling [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from: https://www.fda.gov/media/187302/download2
27. U.S. Food and Drug Administration. The FDA's role in regulating and approving drugs [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/information-consumers-and-patients-drugs/overview-our-role-regulating-and-approving-drugs-video-series
28. U.S. Food and Drug Administration. Data Integrity and Compliance with Drug CGMP [Internet]. Silver Spring (MD): FDA; 2018 [cited 2026 May 21]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
29. U.S. Food and Drug Administration. Advancing Model-Informed Drug Development Program [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from: https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program
30. Modi P, Patel K, Modasiya J. Comparative pathways: reliance and convergence for medicines and medical devices. Int J Med Sci [Internet]. 2026 [cited 2026 May 21]. Available from: doi:10.34218/ijms_04_01_002
31. Modi P, et al. Comparability protocols as a strategic tool for postapproval CMC changes [Internet]. RAPS J Regul Aff. 2026 [cited 2026 May 21]. Available from: https://www.raps.org/resource/comparability-protocols-as-a-strategic-tool-for-postapproval-cmc-changes.html
32. U.S. Food and Drug Administration. Product-Specific Guidances for Generic Drug Development [Internet]. Silver Spring (MD): FDA; 2025 Mar 26 [cited 2026 Jun 22]. Available from: https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development?